TIME & DATE:

July 28th, 2021
4 PM CEST

► REGISTER NOW

ABOUT:

Antibodies are one of the most essential tools used in research, diagnostics, and therapeutics. Their validation is critical to ensure the properties of a given antibody are known. Validation workflows have been well described to determine an antibody’s specificity and sensitivity, but they can be tedious.
In our last seminar on Antibody Validation, we explained how our microfluidic staining solutions can support your antibody validation process. Join us this time to see how we perform Antibody Validation in our lab in a live demonstration.

WHAT YOU WILL LEARN:

• Why it is important to validate an antibody;
• Antibody validation: setting up a strategy, overcoming the challenges;
• How Lunaphore solutions can support your antibody validation process.

The event will feature a DEMO and LIVE Q&A. Register now to reserve your spot.

SPEAKERS:

Dr. Sara Milosevic – Sales Specialist EMEA
Dr. Diego Guerrera – Field Application Specialist

INFO & SUPPORT:

Submit your request to: [email protected]

About the Grant
The Lunaphore Grant Program – Service Lab was designed to provide your lab with the unique opportunity to win free proof-of-concept service projects from the Lunaphore Proof of Concept Service Lab.

The Lunaphore Proof of Concept Service Lab allows researchers to cooperate with Lunaphore scientists through customized proof-of-concept sample processing service projects based on the LabSat® Research or COMET™ platforms, and use the data generated to facilitate the decision-making process for technology adoption. You can find more information about the Lunaphore Proof of Concept Service Lab here.

---

GRANT WINNERS

Lunaphore would like to thank all the applicants for the strong interest in the grant and the numerous excellent-quality applications received.

After carefully reviewing all the applications received, we have selected the winners of the Lunaphore Grant Program – Service Lab.

1st PRIZE WINNER

12-plex project run with COMET™ (Sequential multiplexed immunofluorescence)

Prof. Dr. Ihsan Ekin Demir – Klinikum Rechts Der Isar – Technical University of Munich
“Immunotophography after neoadjuvant therapy in pancreatic cancer microenvironment”

Project description:
Neoadjuvant therapy (neoTx) has dramatically improved the prognosis of patients with locally advanced pancreatic cancer. In a previous study, we demonstrated that neoTx is able to reverse the immunosuppression exerted by malignant cells and selectively deplete myeloid-derived suppressor cells in the peritumoral niche. However, the cell-to-cell interactions between the different subsets of tumor-infiltrating immune cells and their spatial correlation with other basic features of the tumor microenvironment, such as pancreatic neuropathy and stromal activation, remain unknown.  The novel Lunaphore high-plex technology will allow us to penetrate deep into the geography of pancreatic cancer and discover potential therapeutic targets for neoadjuvant approaches.

2nd PRIZE WINNER

6-plex project run with LabSat® Research (TSA-based multiplexed immunofluorescence)

Dr. Patricia Gaule – Department of Pathology, Yale School of Medicine
“Cross Validation of a Manual mQIF panel with Lunaphore LabSat and optimization for clinical assay provision.”

Project description:
The Specialized Translation Services Laboratory (STS Lab) is CLIA certified lab within Yale Pathology Labs providing CLIA standard mQIF services within and outside of Yale University. The emergence of immunotherapies throughout the last decade has demonstrated the unmet need of an assay capable of measuring multiple immune cell markers (IC) in tandem. Our goal is to design a mQIF assay to be made available to treating physicians allowing additional information generated to make an informed clinical decision. IC of PD-L1, CD8, CD20, CD4, and CD68 will be assessed using Lunaphore LabSat using 9 whole tissue samples and 1 TMA (485 NSCLC cases). Results will be correlated with patient demographics, treatments, and survival statistics to assess the prognostic/predictive power.

---

Do you want to know more?

Click on the button below to discuss with our representatives.

Ask our team

We are happy to announce the Lunaphore Service Lab Grant Program 2021.

At Lunaphore, we are committed to helping in the research of immuno-oncology by providing innovative instruments based on a microfluidic technology to perform mIF staining. Thanks to the Lunaphore Service Lab Grant Program your laboratory has the unique opportunity to win a free 6 or 12-plex staining service performed on LabSat® Research or Comet™ platforms.

Timelines:
Applications submission deadline: April 30^th, 2021
Award winners notification: May 15^th, 2021

THE WINNERS WILL BE ANNOUNCED ON MONDAY MAY 17th. 

Visit the Grant Program dedicated page to learn more.

---

Interact with our team and discover the potential of our technology by attending this unique event:

Lunaphore Grant Program – Service Lab Webinar

April 26 2021 | 5 PM CEST – 11AM EDT

Join this Webinar to learn more about our technology, get more details, and ask questions about our Service Lab Grant Program.

 

---

Do you want to know more?

Click on the button below and one of our representatives will get in touch with you.

Ask our team

About the Grant Program
The Lunaphore Immuno-Oncology Grant Program has been designed with the intention of helping in the research of immuno-oncology by providing innovative instruments based on a microfluidic technology to perform mIF staining.

Among other prizes, the Immuno-Oncology Grant Program featured the unique opportunity to win a free LabSat® Research or COMET™ Instrument. For more information about the Program, please visit the dedicated page.

Grant Program Winners
The submission is now closed. Lunaphore would like to thank all the applicants for the strong interest in the grant and the numerous excellent-quality applications received.

After carefully reviewing all the applications received, we have selected the winners of the Lunaphore Immuno-Oncology Grant Program.

---

LabSat® Research Immuno-Oncology Grant

1^st PRIZE WINNER:
Dr. Arman Rahman – Conway Institute, University College Dublin
“Exploration of the Interplay between Master Transcriptional Regulators and Immune Cells within the Tumour Microenvironment of Breast Cancer AND Comparison of subcutaneous adipose tissue (SAT) inflammatory profiles in individuals with and without COVID-19 infection.”

Project description:
Precision Oncology Ireland (POI) is a consortium of 5 Irish Universities, 6 Irish cancer research charities, and 8 companies aiming to develop new diagnostics and therapeutics for personalised cancer treatment. The POI Tissue Imaging Platform provides state-of-the-art automated immunohistochemistry and digital pathology services for high-throughput biomarker validation to all consortium members and external collaborators. Two ongoing funded programs include characterisation of immune and non-immune markers in (1) breast cancer tissue and (2) subcutaneous adipose tissue (SAT) in individuals with COVID-19 infection using fluorescence multiplexing. The LabSat® Research system, which offers ultra-rapid turnover time for multiplex staining, will enhance the research output of the POI Tissue Imaging Platform significantly.

2^nd PRIZE WINNER:
Dr. Nicolas van Baren – de Duve Institute, UCLouvain
“Restoring anti-tumour immunity in endometrial cancer by shutting down COX-2-mediated constitutive IDO1 expression with celecoxib”

Project description:
Indoleamine 2,3-dioxygenase 1 (IDO1) protects tumours from T-lymphocyte attack by depleting surrounding tryptophan. Its tumoural expression is induced by cyclooxygenase-2 (COX-2) and autocrine prostaglandin-E2, and can be blocked by celecoxib, a selective COX-2 inhibitor. We have launched a proof-of-principle clinical trial to investigate the effect of celecoxib on tumoural IDO1 expression and nature, abundance, distribution and phenotype of tumour-infiltrating T cells. Patients with newly diagnosed endometrial carcinoma will receive celecoxib before tumour surgery. FFPE tumour sections from pre-treatment biopsy and surgical specimen will be stained by multiplexed immunofluorescence (pan-cytokeratin, IDO1, CD3 and CD8 markers) and quantified by computerized image analysis to investigate the in vivo effects of COX-2 inhibition. The LabSat Research instrument will help us achieve the high reproducibility, high quality and gain of time required for this study.

---

COMET™ Immuno-Oncology Grant 

1^st PRIZE WINNER:
Prof. Johann de Bono – Institute of Cancer Research and Royal Marsden Hospital
“Targeting adenosinergic signalling in lethal prostate cancers.”

Project description:
Prostate cancer is a leading cause of male cancer mortality. Tremendous advances in cancer immunotherapies have had minimal impact on prostate cancer management likely due to potent immunosuppressive barriers that are operative. The Cancer Biomarkers Group led by Professor Johann de Bono at the Institute of Cancer Research (United Kingdom) will utilize the COMETTM platform to perform hyper-plex immunofluorescence on human prostate tumour biopsies to dissect complex tumour-immune interactions that lead to immunoresistance. We believe this technology will provide insights into prostate cancer biology that can be rapidly translated into precision immunotherapies that will improve the outcomes of patients with lethal prostate cancers.

2^nd PRIZE WINNER:
Dr. Adeeb Rahman – Mount Sinai School of Medicine
“Enabling High Dimensional Spatial Functional Genomics via the COMET Platform.”

Project description:
We have recently established a novel technology platform, which utilizes protein-based barcodes (Pro-Codes) to enable 100s of genetic perturbations to be detected in parallel in tissues and tumors. This project aims to adapt this technology to the COMET platform to establish an integrated workflow to comprehensively analyze the impact of genetic perturbations on cell phenotypes and tissue architecture in the tumor microenvironment.

---

Do you want to know more?

Click on the button below to discuss with our representatives.

Ask our team

We are happy to announce the Lunaphore Immuno-Oncology Grant Program.

At Lunaphore, we are committed to helping in the research of immuno-oncology by providing innovative instruments based on a microfluidic technology to perform mIF staining. Thanks to the Lunaphore Immuno-Oncology Grant Program your lab has the unique opportunity to win a free LabSat® Research or COMET™ Instrument.

Timelines:
Applications submission deadline: December 1^st, 2020
Award winners notification: December 8^th, 2020

Visit the Lunaphore Immuno-Oncology dedicated page to learn more.

---

Interact with our team and discover the potential of our technology by attending this unique event:

Immuno-Oncology Grant Program Webinar

November, 18 2020 | 5 PM CET

Join this Webinar to learn more about our technology, get more details, and ask questions about our Immuno-oncology Grant Program.

 

---

Do you want to know more?

Click on the button below and one of our representatives will get in touch with you.

Ask our team

We would like to invite you to join us at these two upcoming events:

• Society for Immunotherapy of Cancer’s 35^th Anniversary Annual Meeting  (SITC 2020)
• 32nd Congress of the European Society of Pathology and XXXIII International Congress of the IAP (ESP-IAP Congress 2020) 

Both of these events have been reimagined as virtual and interactive experiences.

---

Society for Immunotherapy of Cancer’s 35^th Anniversary Annual Meeting  (SITC 2020)

November, 11-14 2020

The conference programme features the most recent advances in tumor immunology and cancer immunotherapy in research.

Visiting our virtual booth, you will discover our ultra-rapid tissue staining instrument – LabSat® Research –  and learn more about its key applications for the study of the tumor microenvironment, such as:

– TSA-multiplexed immunofluorescence;
– Sequential multiplexed immunofluorescence (coming soon);
– FFPE & FS immunohistochemistry.

In the Innovation Showcase Area, you can have a glance at the beta version of our next-generation instrument: Comet.
Comet is a fully-automated staining and imaging platform that performs hyper-plex immunofluorescence assays.
Thanks to our cutting-edge microfluidic technology, these assays can be performed using only off-the-shelf, label-free primary antibodies.

The congress is free-access for all the SITC members.

 

Comet is still in development and not for sale.  We are currently looking for collaborators: if you are interested in becoming an early adopter of the Comet prototype, get in touch with us. Visit the Innovation Showcase Area to learn more.

32nd Congress of the European Society of Pathology and XXXIII International Congress of the IAP (ESP-IAP Congress 2020) 

December, 6-8 2020

Now delivered as a virtual event, the ESP/IAP Virtual Congress 2020 is an exciting opportunity for the global pathology world to get in touch with the best innovations in the field.

New data generated with our microfluidic technology for in-situ tissue analytics and cancer research will be featured in two ePosters presentations:

PS-11-032; Comparative histopathological and digital scoring between microfluidic and standard immunohistochemistry for p40 and TTF1 on non-small cell lung carcinoma.

PS-15-028; Microfluidic-based automated chromogenic RNA in situ hybridization.

Register now and benefit from the reduced fees:

 

---

Do you want to know more?

Click on the button below and one of our representatives will get in touch with you.

Ask our team

The 7th Immunotherapy of Cancer Conference is going virtual and Lunaphore is participating in the event. Featuring the latest developments in cancer immunotherapy, the conference represents a global forum for discussion of translational research in the field of immuno-oncology.

Our products and technology for in-situ tissue analytics will be featured in a LIVE Satellite Symposium as well as in an ePoster presentation.

Joining the two presentations you will learn more on:

• The key features of our microfluidic precision circuit combined with instantaneous temperature control;
• How we automate staining and imaging of hyper-plex immunofluorescence assays;
• How to perform immunofluorescence multiplexing in short timeframes using off-the-shelf, label-free antibodies.

Can’t attend? Fill in this form and we will send you a link to the recordings after the event.

---

LIVE Satellite Symposium
“Rapid hyper-plex staining and simultaneous imaging for immunophenotyping of tissue sections”

Speaker: Diego Dupouy, Ph.D.
When: 3 Oct 2020 | 11:45 CEST – afterwards on-demand.

Abstract
The simultaneous detection of biomarkers on tissue samples plays a fundamental role in the study of the tumor microenvironment. Multiplexed immunofluorescence tools have demonstrated to be key enablers in these endeavors. Available techniques to perform high-plex staining require intensive manual handling, are highly time-consuming or require special labeling of primary antibodies. Here we present a highly automated, extremely rapid hyper-plex approach to stain and image tissue samples using label-free primary antibodies in combination with off-the-shelf fluorescently labeled secondary antibodies.

ePoster presentation
“Fast automated microfluidic-based multiplexed immunofluorescence for tumor microenvironment analysis”

Speaker: Alexandre Kehren, M.Sc.
When: On-demand, 2-3 Oct 2020 | P03.07

Abstract
Immuno-oncology and targeted molecular therapies have acquired a central role in the treatment of multiple cancers. Consequently, high-throughput biomarker analysis and tumor immune profiling have seen increased demand. Multiplexed immunoassays are a powerful tool to address these needs, but still time- and resource-consuming. Here we present how we developed a fast and automated high-plex fluorescent immunostaining procedure, using a microfluidic-based device, that can be easily implemented as a routine assay.

---

Do you want to know more?

Click on the button below and one of our representatives will get in touch with you.

Ask our team

Lunaphore announces the second closing of its Series C round totaling CHF 25M.

The CHF 2M Series C2 financing was provided by the Swiss Entrepreneurs Fund, who invested a total of CHF 5M in the company. The fund is linked to the Swiss Entrepreneurs Foundation, whose main focus is to invest in Swiss start-ups and SMEs in the growth phase (internationalization) with the goal of bridging the financing gap in Swiss innovation.

Read the full press release

European Congress of Pathology 2019, Nice

---

Earlier this month, we were present at the European Congress of Pathology in Nice. A wide audience made of pathologists, lab managers, clinical researchers and medtech distributors, visited our booth to get to know more about our rapid staining instrument LabSat™.

We also presented our microfluidic technology to a large audience as well as 2 scientific posters which can be downloaded on the links below:

Presentation:

“Ultra-fast and automated immunohistofluorescent multistaining using a microfluidic tissue processor” by M.A. Comino

Posters:

“Fast immunofluorescence multiplexing using a microfluidic precision autostainer and tyramide signal amplification” by A. Kehren – VIEW POSTER

“Microfluidic Immunohistochemistry for Rapid Detection of Diagnostic and Predictive Biomarkers on Non-Small Cell Lung Carcinoma” by M.G. Procopio – VIEW POSTER

___ 

Histalim Multiplex Histopathology Annual Meeting, Montpellier 

---

We attended as well the Histalim Multiplex Histopathology Annual Meeting in Montpellier with a booth and a 30 minute talk as sponsors of the event.

This meeting brings together the main industry players of the multiplexing applications. Here, we had the chance to present our technology and discuss about how it could improve research workflows for multiplexed IF and protocol optimization.

 

Presentation:

“Fast multiplex immunofluorescence using a microfluidic precision autostainer and tyramide signal amplification” by A. Kehren

___ 

Convergence in Oncology Summit, Lausanne

---

Our CEO, Ata Tuna Ciftlik, participated at the Convergence in Oncology Summit in the session around Medical Devices in Oncology, discussing the potential impact of our technology on cancer research and clinical practice in the upcoming years.

___ 

Annual Danish ERFA IHC meeting, Vejle 

---

We opened the annual meeting presenting Lunaphore’s products and our microfluidic technology to the Danish IHC community.

Presentation:

“Ultra-rapid automated IHC staining based on novel microfluidic tissue processor” by M.G. Procopio

___ 

5th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference, Paris

---

This was our first time at the CICON conference, which has a focus on immunotherapy and cancer research. We sponsored this conference with a booth to discuss with attendees the potential of LabSat™ Research in their activities.

Would you like to receive the slide decks we presented or would like to know more about our products?

Get in touch! – [email protected]